ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

LGND Ligand Pharmaceuticals Incorporated

72.32
0.90 (1.26%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ligand Pharmaceuticals Incorporated LGND NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.90 1.26% 72.32 17:12:13
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
71.77 70.855 72.70 72.32 71.42
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/3/202412:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202416:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202417:12EDGAR2Form 144 - Report of proposed sale of securities
01/3/202415:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202417:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202417:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202417:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:49EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
28/2/202417:05EDGAR2Form 144 - Report of proposed sale of securities
28/2/202416:43EDGAR2Form 144 - Report of proposed sale of securities
27/2/202406:24EDGAR2Form 8-K - Current report
16/2/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202405:26EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202414:39EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202418:30GLOBEHenlius and Sermonix Announce Strategic Collaboration and..
05/1/202416:40DJNLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection..
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202314:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202314:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202307:25EDGAR2Form 8-K - Current report
01/12/202307:20GLOBEPalvella Therapeutics and Ligand Pharmaceuticals Expand..
28/11/202308:01GLOBESermonix Pharmaceuticals Announces Five Abstracts Accepted..
09/11/202320:48EDGAR2Form 8-K/A - Current report: [Amend]
09/11/202316:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:08EDGAR2Form 8-K - Current report
06/11/202308:00GLOBESermonix Pharmaceuticals Announces JCO Precision Oncology..
18/10/202308:03EDGAR2Form 8-K - Current report
18/10/202307:00GLOBEOvid Therapeutics and Ligand Pharmaceuticals Enter into a..
03/10/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202308:00GLOBESermonix Pharmaceuticals Shares Results of EQUALS 2 Survey..
27/9/202307:38EDGAR2Form 8-K - Current report
26/9/202315:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202315:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202316:26EDGAR2Form 8-K - Current report
14/8/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:02EDGAR2Form 8-K - Current report
17/7/202307:45GLOBENovan Enters into Agreement to Sell Substantially All of its..
10/7/202317:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202317:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202308:00GLOBESermonix Pharmaceuticals to Present Two Posters at The..
05/6/202308:01GLOBESermonix Pharmaceuticals Shares ASCO Poster Presentation on..
25/5/202316:00GLOBESermonix Pharmaceuticals to Share Longer Patient Follow-up..

Su Consulta Reciente

Delayed Upgrade Clock